This page explains the science behind tibial nerve stimulation in plain language - including the part that seems counterintuitive - and where Stedara sits in relation to that evidence.
The purpose here is not to overstate the science, but to explain clearly why ankle-based stimulation is not arbitrary, how it relates to the tibial nerve, and why that matters for urgency-related bladder symptoms.
The tibial nerve is accessible near the inner ankle, where surface stimulation can reach it through the skin.
That nerve connects into the same sacral network involved in bladder signalling.
It explores the same principle in a self-directed, real-world situational format rather than a clinic session model.
When people first hear that stimulating the ankle might influence bladder urgency, the reasonable response is scepticism. The ankle and the bladder seem to have nothing to do with each other. Understanding why this actually makes sense requires a short explanation of how the relevant nerve pathways connect.
The key is the tibial nerve. This nerve runs along the inner side of the lower leg and passes close to the surface near the ankle - specifically, just above and behind the bony prominence on the inner ankle called the medial malleolus. At this point, the nerve is accessible through the skin, which is why the ankle is the target location.
The tibial nerve is a branch of the sciatic nerve, which connects into the sacral nerve plexus. This is the same nerve network that carries signalling between the bladder, the urethra, and the central nervous system. The tibial nerve and the nerve pathways involved in bladder control share a common root.
This shared root is the reason that stimulation applied at the ankle - to the tibial nerve - can influence signals carried along pathways involved in bladder function. It is not that the ankle does something to the bladder directly. It is that stimulating the tibial nerve sends signals into a network that includes the pathways involved in bladder urgency.
Understanding exactly why nerve stimulation can reduce urgency requires a brief look at how urgency is generated in the first place.
The bladder sends signals to the nervous system as it fills. In people with overactive bladder or urge-predominant symptoms, these signals can fire with excessive intensity, arrive earlier than the bladder's actual capacity would warrant, or produce urgency that is difficult to suppress voluntarily. The nervous system processes these signals, and the experience of urgency is the result.
One well-established principle in neuroscience is that nerve signals can interact with and influence each other. This is sometimes described using the concept of gating - the idea that one set of nerve signals, travelling through overlapping pathways, can reduce the perceived intensity of another. In pain science, this is the basis for several widely used treatments: TENS for pain, for example, works in part by introducing competing nerve signals that reduce the experience of pain signals travelling similar pathways.
The hypothesis underlying tibial nerve stimulation for bladder urgency follows the same logic. By introducing stimulation along the tibial nerve - which connects into the same sacral nerve network involved in bladder signalling - the aim is to influence how urgency signals are processed. When it is helpful, urgency may feel less intense, easier to delay, or less likely to escalate quickly.
This is not a guaranteed outcome. Responses vary between individuals, and the degree of effect differs. But the mechanism is not speculative - it draws on principles that are established in neuroscience and applied in other areas of clinical practice.
Transcutaneous tibial nerve stimulation - TTNS, sometimes also written as PTNS for percutaneous when a fine needle electrode is used instead of surface pads - has been studied in the context of overactive bladder and urgency-related urinary symptoms for several decades.
The clinical picture is genuinely mixed, as it is for most interventions in this area. Some studies show meaningful reductions in urgency frequency, urgency incontinence episodes, and quality-of-life scores in people who completed a course of treatment. Some show more modest effects. The variation in results reflects real variation in how people respond, differences in study design and patient populations, and the difficulty of running controlled trials in this area.
TTNS delivered in a clinical setting typically uses professional equipment, standardised protocols, and a defined course of sessions. It is administered by a trained practitioner and is part of a broader assessment and management process.
Stedara is informed by the same underlying principle as TTNS: that stimulation applied near the tibial nerve at the ankle may influence the nerve pathways involved in bladder urgency. The delivery tool is a consumer TENS unit - the same technology used in TTNS - applied to the same general area. Use of a consumer TENS unit in this context is not a medical recommendation.
What Stedara does differently is in the application rather than the principle.
Clinical TTNS is typically delivered as a regular scheduled treatment - a fixed number of sessions, in a clinical environment, over a defined period. The aim is cumulative effect over time. Stedara is designed around a different use pattern: applying the method in the specific situations where urgency is most disruptive, using the effect in that moment, and judging results by what changes in those situations.
This is not presented as a replacement for clinical TTNS or for medical care. It is a structured, self-directed approach for appropriately screened adults who want to explore this principle in the real-world situations where urgency matters most to them.
The existence of clinical TTNS does not mean that self-directed use is equivalent to clinical treatment. Stedara is not a clinical intervention and does not replace medical care.
Stedara is explicit about what it does not do: it does not diagnose, it does not treat underlying conditions, and it does not guarantee results. What it does is provide a structured, practical method for using an established principle in a self-directed way, with honest guidance on how to judge whether it is worth continuing.
Tibial nerve stimulation and consumer TENS use are generally considered safe within appropriate parameters, but there are situations where proceeding without medical review is not appropriate.
These situations require proper evaluation. Stedara includes a safety and eligibility screening process, but that screening is not a substitute for medical assessment when symptoms are new, unexplained, or changing.
Stedara requires eligibility and safety screening before access. This ensures the program is a reasonable option and that there are no contraindications that would make it unsuitable for you.
Screening is not diagnostic and does not rule out underlying medical conditions. It is designed to identify safety considerations and whether the program is a reasonable option to explore.
No. Understanding the mechanism does not predict individual response. The method is intended as a structured trial, and outcomes can vary.
No. The program explains a consumer-use approach based on known concepts. It is not the same as individualised clinical treatment or supervised care.
Yes. Placement and intensity are important for the method being trialled. The program provides guidance on how to approach this safely within defined limits.
Responses to stimulation can vary. Not feeling a specific response does not automatically mean the method is effective or ineffective. The program provides guidance on how to interpret this cautiously.
You should stop if you are outside the program guidance, develop unexpected symptoms, or are unsure about safety. Medical advice should be sought if there is any concern.